Semaglutide Concurrently Improves Vascular and Liver Indices in Patients With Type 2 Diabetes and Fatty Liver Disease
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Context: The cardiovascular benefits of semaglutide are established; however, its effects on surrogate vascular markers and liver function are not known. Objective: To investigate the effects of semaglutide on vascular, endothelial, and liver function in patients with type 2 diabetes (T2DM) and nonalcoholic fatty liver disease (NAFLD). Methods: Overall, 75 consecutive subjects with T2DM and NAFLD were enrolled: 50 patients received semaglutide 1 mg (treatment group) and 25 patients received dipeptidyl peptidase 4 inhibitors (control group). All patients underwent a clinical, vascular, and hepatic examination with Fibroscan elastography at 4 and 12 months after inclusion in the study. Results: Treatment with semaglutide resulted in a reduction of Controlled Attenuation Parameter (CAP) score, E fibrosis score, NAFLD fibrosis score, Fibrosis-4 (FIB-4) score and perfused boundary region (PBR) at 4 and at 12 months (P < .05), contrary to controls. Patients treated with semaglutide showed a greater decrease of central systolic blood pressure (SBP) (−6% vs −4%, P = .048 and −11% vs −9%, P = .039), augmentation index (AIx) (−59% vs −52%, P = .041 and −70% vs −57%, P = .022), and pulse wave velocity (PWV) (−6% vs −3.5%, P = .019 and −12% vs −10%, P = .036) at 4 and at 12 months, respectively. In all patients, ΔPWV and ΔPBR were correlated with a corresponding reduction of CAP, E fibrosis, NAFLD fibrosis, and FIB-4 scores. Conclusion: Twelve-month treatment with semaglutide simultaneously improves arterial stiffness, endothelial function, and liver steatosis and fibrosis in patients with T2DM and NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“GLP-1 RAs, particularly semaglutide, have been shown to reduce liver steatosis and improve markers of liver inflammation and fibrosis in patients with type 2 diabetes and metabolic dysfunction-associated steatotic liver disease.34, 35, 36”
From The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions (2025) · cites this paper as [35]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Hattori, Y., Jojima, T., Tomizawa, A., Satoh, H., Hattori, S., Kasai, K., & Hayashi, T. (2010) · Diabetologia · doi:10.1007/s00125-010-1831-8 · Cited by 183 · cited 1×
“Treatment with liraglutide or exendin-4 increased endothelial NO synthase (eNOS) phosphorylation and NO production in a 5 ′ AMP-activated protein kinase (AMPK)-dependent manner [27, 28].”
BackgroundRetractedChalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis
Riazi, K., Azhari, H., Charette, J. H., Underwood, F. E., King, J. A., Afshar, E. E., Swain, M. G., Congly, S. E., Kaplan, G. G., & Shaheen, A.-A. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(22)00165-0 · Cited by 2,246 · cited 1×
“Nonalcoholic fatty liver disease (NAFLD) is now considered the most frequent liver disease worldwide, with its global prevalence reaching up to 32.4% [1].”
BackgroundInfluentialA Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039 · cited 1×
“…to our results due to the use of Fibroscan, was a 72-week, double-blind phase 2 trial, involving patients with biopsy-confirmed NASH and liver fibrosis of stage F1, F2, or F3, where patients were assigned to once-daily semaglu-tide at a dose of 0.1, 0.2, or 0.4 mg or corresponding placebo [34].”
MethodInfluentialBan, K., Noyan-Ashraf, M. H., Hoefer, J., Bolz, S.-S., Drucker, D. J., & Husain, M. (2008) · Circulation · doi:10.1161/circulationaha.107.739938 · Cited by 1,057 · cited 1×
“GLP-1R expression has been detected in mouse mesenteric or coronary arteries in immunohistochemistry studies utilizing GLP-1R antibodies; however, their validity has been proven to be nonspecific in some cases [24].”
BackgroundNyström, T., Gutniak, M. K., Zhang, Q., Zhang, F., Holst, J. J., Ahrén, B., & Sjöholm, Å. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00237.2004 · Cited by 680 · cited 1×
“On the other hand, in human models, Western blotting has confirmed GLP-1R protein expression in human umbilical vein endothelial cells (HUVECs) [25], but in human heart samples, full-length GLP1-R mRNA transcripts have not been detected [26].”
BackgroundLoomba, R., Abdelmalek, M. F., Armstrong, M. J., Jara, M., Kjær, M. S., Krarup, N., Lawitz, E., Ratziu, V., Sanyal, A. J., Schattenberg, J. M., et al. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00068-7 · Cited by 533 · cited 1×
“…of 27 kg/m² were assigned to semaglutide 2.4 mg or placebo, no statistically significant difference between the 2 groups in the proportion of patients who had an improvement in liver fibrosis of 1 stage or more was noted after 48 weeks, and the same applied for the endpoint of NASH resolution [33].”
InfluentialGupta, N. A., Mells, J., Dunham, R. M., Grakoui, A., Handy, J., Saxena, N. K., & Anania, F. A. (2010) · Hepatology · doi:10.1002/hep.23569 · Cited by 532 · cited 1×
“GLP-1 ligands are able to promote the phosphorylation of AKT, an effect that subsequently triggers the postreceptor signaling cascade downstream of insulin receptor substrate-2 (IRS-2), leading to reduced storage of hepatocyte triglycerides and, therefore, reduced hepatic steatosis [39].”
BackgroundLekakis, J., Abraham, P., Balbarini, A., Blann, A., Boulanger, C. M., Cockcroft, J., Cosentino, F., Deanfield, J., Gallino, A., Ikonomidis, I., et al. (2011) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/1741826711398179 · Cited by 315 · cited 1×
“However, due to the detrimental effects of diabetes on the endothelium early in the course of the disease, endothelial dysfunction has been considered a reliable predictor of cardiovascular disease in recent years [7].”
BackgroundSelf-citationGLP-1 Receptor Expression Within the Human Heart
Baggio, L. L., Yusta, B., Mulvihill, E. E., Cao, X., Streutker, C. J., Butany, J., Cappola, T. P., Margulies, K. B., & Drucker, D. J. (2018) · Endocrinology · doi:10.1210/en.2018-00004 · Cited by 312 · cited 1×
“On the other hand, in human models, Western blotting has confirmed GLP-1R protein expression in human umbilical vein endothelial cells (HUVECs) [25], but in human heart samples, full-length GLP1-R mRNA transcripts have not been detected [26].”
BackgroundNevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., & Sasso, F. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021703 · Cited by 286 · cited 1×
“Semaglutide, a long-acting GLP-1RA, presents the most beneficial metabolic actions and has been under the spotlight for its possible role in NAFLD [14, 15].”
BackgroundErdogdu, Ö., Nathanson, D., Sjöholm, Å., Nyström, T., & Zhang, Q. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.04.022 · Cited by 229 · cited 1×
“Treatment with liraglutide or exendin-4 increased endothelial NO synthase (eNOS) phosphorylation and NO production in a 5 ′ AMP-activated protein kinase (AMPK)-dependent manner [27, 28].”
BackgroundFlint, A., Andersen, G., Hockings, P., Johansson, L., Morsing, A., Sundby Palle, M., Vogl, T., Loomba, R., & Plum‐Mörschel, L. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16608 · Cited by 224
Ikonomidis, I., Pavlidis, G., Thymis, J., Birba, D., Kalogeris, A., Kousathana, F., Kountouri, A., Balampanis, K., Parissis, J., Andreadou, I., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015716 · Cited by 199
Self-citationZhou, Y., Zhou, X., Wu, S., Fan, D., Van Poucke, S., Chen, Y., Fu, S., & Zheng, M. (2018) · Hepatology Communications · doi:10.1002/hep4.1155 · Cited by 150 · cited 1×
“In the study by Yu et al [45], it was found that significant fibrosis in NAFLD had an independent association with increased arterial stiffness after adjustment for cardiovascular risk factors, and the results in other studies were similar [46-48].”
ResultLambadiari, V., Pavlidis, G., Kousathana, F., Varoudi, M., Vlastos, D., Maratou, E., Georgiou, D., Andreadou, I., Parissis, J., Triantafyllidi, H., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0646-z · Cited by 146 · cited 2×
“In a study by Lambadiari et al [11], 6-month treatment with liraglutide reduced PWV (11.8 ± 2.5 vs 10.3 ± 3.3 m/s) in recipients, compared to subjects who received only metformin, and this positive effect was reproduced in another report by the same group, where liraglutide resulted in a…”
ResultInfluentialSelf-citationRentzeperi, E., Pegiou, S., Koufakis, T., Grammatiki, M., & Kotsa, K. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12030454 · Cited by 140 · cited 1×
“In agreement with previous studies [49], in our study we found that women who received semaglutide presented a greater BMI reduction than men.”
ResultBatzias, K., Antonopoulos, A. S., Oikonomou, E., Siasos, G., Bletsa, E., Stampouloglou, P. K., Mistakidi, C.-V., Noutsou, M., Katsiki, N., Karopoulos, P., et al. (2018) · Journal of Diabetes Research · doi:10.1155/2018/1232583 · Cited by 140 · cited 1×
“…PWV (pooled mean difference [MD] = − 1.97; 95% CI, − 2.65 to − 1.30; P < .001), but, surprisingly, did not present the same beneficial effect on flow-mediated dilation of the brachial artery (FMD), which is an index of endothelial function (pooled MD = 2.37%; 95% CI, − 0.51 to 5.25; P = .107) [16].”
BackgroundInfluentialSelf-citationLuna-Marco, C., de Marañon, A. M., Hermo-Argibay, A., Rodriguez-Hernandez, Y., Hermenejildo, J., Fernandez-Reyes, M., Apostolova, N., Vila, J., Sola, E., Morillas, C., et al. (2023) · Redox Biology · doi:10.1016/j.redox.2023.102849 · Cited by 117 · cited 1×
“In a previous study by our group, 6-month treatment with liraglutide reduced malondialdehyde and protein carbonyls, which are markers of oxidative stress; similar effects have been reproduced in other studies [11, 30].”
ResultFang, Y., Ji, L., Zhu, C., Xiao, Y., Zhang, J., Lu, J., Yin, J., & Wei, L. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.602574 · Cited by 108 · cited 1×
“GLP-1R stimulation increases autophagy and mitigates endoplasmic reticulum (ER) stress and, therefore, it inhibits hepatocyte apoptosis and prevents further progression of liver damage [42].”
BackgroundRizzo, M., Chandalia, M., Patti, A. M., Di Bartolo, V., Rizvi, A. A., Montalto, G., & Abate, N. (2014) · Cardiovascular Diabetology · doi:10.1186/1475-2840-13-49 · Cited by 107
Jojima, T., Uchida, K., Akimoto, K., Tomotsune, T., Yanagi, K., Iijima, T., Suzuki, K., Kasai, K., & Aso, Y. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.04.001 · Cited by 105 · cited 1×
“…reduced the intimal and medial area by ∼ 66% and ∼ 11%, respectively and reduced inflammatory markers [18], and this anti-inflammatory, antiproliferative effect on vascular remodeling has been observed with GLP-1RAs in previous in vitro studies with vascular smooth muscle cells [19, 20].”
BackgroundNon-Alcoholic Fatty Liver Disease: From Pathogenesis to Clinical Impact
Caturano, A., Acierno, C., Nevola, R., Pafundi, P. C., Galiero, R., Rinaldi, L., Salvatore, T., Adinolfi, L. E., & Sasso, F. C. (2021) · Processes · doi:10.3390/pr9010135 · Cited by 104
Glucagon-like peptide-1 receptor action in the vasculature
Almutairi, M., Al Batran, R., & Ussher, J. R. (2019) · Peptides · doi:10.1016/j.peptides.2018.09.002 · Cited by 99 · cited 1×
“The presence of GLP-1 receptors (GLP-1R) in endothelial cells is a matter of debate [23].”
BackgroundVolpe, S., Lisco, G., Fanelli, M., Racaniello, D., Colaianni, V., Triggiani, D., Donghia, R., Crudele, L., Rinaldi, R., Sabbà, C., et al. (2022) · Nutrients · doi:10.3390/nu14214673 · Cited by 84 · cited 1×
“In the study by Volpe et al [36], who enrolled a very similar cohort to ours, semaglutide 0.5 mg for 52 weeks led to at least 1-class reduction in the 4-point semiquantitative staging in NAFLD diagnosed via ultrasound, along with the expected improvements in liver enzymes, glycemic control, and…”
MethodInfluentialAcierno, C., Caturano, A., Pafundi, P. C., Nevola, R., Adinolfi, L. E., & Sasso, F. C. (2020) · Exploration of Medicine · doi:10.37349/emed.2020.00019 · Cited by 73
Zhang, M., Bai, Y., Ye, P., Luo, L., Xiao, W., Wu, H., & Liu, D. (2011) · Clinical Cardiology · doi:10.1002/clc.20956 · Cited by 72 · cited 1×
“Arterial stiffness, as assessed by pulse wave velocity (PWV), has also been found to be elevated in T2DM [8].”
BackgroundTuttolomondo, A., Cirrincione, A., Casuccio, A., Del Cuore, A., Daidone, M., Di Chiara, T., Di Raimondo, D., Corte, V. D., Maida, C., Simonetta, I., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01183-5 · Cited by 69
Zhu, Y., Xu, J., Zhang, D., Mu, X., Shi, Y. Y., Chen, S., Wu, Z., & Li, S. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.769069 · Cited by 65 · cited 1×
“…along with alanine aminotransferase (weighted mean difference [WMD] = − 3.82 IU/L; 95% CI, − 7.04 to − 0.60; P = .02), aspartate aminotransferase (WMD = − 2.4 IU/L; 95% CI, − 4.55 to − 0.25; P = .03), HbA1c, total cholesterol, and triglycerides, whereas no improvement was shown in FIB-4 index [37].”
InfluentialRizvi, A. A., Patti, A. M., Giglio, R. V., Nikolic, D., Amato, A., Al-Busaidi, N., Al-Rasadi, K., Soresi, M., Banach, M., Montalto, G., et al. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1067299 · Cited by 52 · cited 1×
“In general, whether the vasculoprotective action of GLP1-RAs is mainly attributed to local GLP-1R stimulation or the peripheral effects that improve atherosclerosis is yet to be elucidated [31, 32]; however, the anti-inflammatory properties of this drug class indisputably play a pivotal role.”
BackgroundClinical use of liraglutide in type 2 diabetes and its effects on cardiovascular risk factors
Varanasi, A., Patel, P., Makdissi, A., Dhindsa, S., Chaudhuri, A., & Dandona, P. (2012) · Endocrine Practice · doi:10.4158/ep11169.or · Cited by 50 · cited 1×
“The well-established reduction of chronic, low-grade inflammation and oxidative stress with GLP-1RAs also plays a decisive role [43, 44], and possibly explains the correlation between the enhancement in vascular indices and liver steatosis in our sample.”
BackgroundLee, H. A., & Kim, H. Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119324 · Cited by 48 · cited 1×
“Semaglutide, a long-acting GLP-1RA, presents the most beneficial metabolic actions and has been under the spotlight for its possible role in NAFLD [14, 15].”
BackgroundGLP-1RAs and cardiovascular disease: is the endothelium a relevant platform?
Menghini, R., Casagrande, V., Rizza, S., & Federici, M. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02124-w · Cited by 47 · cited 1×
“The endothelium may present a direct target for GLP-1RAs, as it is suggested by the presence of the corresponding receptor in endothelial cells and macrophages, and by several in vitro studies where a protective role of GLP-1RA treatment has been demonstrated [9].”
BackgroundLambadiari, V., Thymis, J., Kouretas, D., Skaperda, Z., Tekos, F., Kousathana, F., Kountouri, A., Balampanis, K., Parissis, J., Andreadou, I., et al. (2021) · Antioxidants · doi:10.3390/antiox10091379 · Cited by 42 · cited 1×
“The well-established reduction of chronic, low-grade inflammation and oxidative stress with GLP-1RAs also plays a decisive role [43, 44], and possibly explains the correlation between the enhancement in vascular indices and liver steatosis in our sample.”
BackgroundSelf-citationYu, X., Zhao, Y., Song, X., & Song, Z. (2014) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b1400028 · Cited by 36 · cited 1×
“In the study by Yu et al [45], it was found that significant fibrosis in NAFLD had an independent association with increased arterial stiffness after adjustment for cardiovascular risk factors, and the results in other studies were similar [46-48].”
ResultSemaglutide in Obesity: Unmet Needs in Men
Jensterle, M., Rizzo, M., & Janež, A. (2023) · Diabetes Therapy · doi:10.1007/s13300-022-01360-7 · Cited by 36 · cited 1×
“Moreover, the impact of sex hormones in the regulation of feeding behavior and the different rate of gastric emptying have been proposed for this difference between the sexes [50].”
BackgroundPan, X., Yang, L., Wang, S., Liu, Y., Yue, L., & Chen, S. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110196 · Cited by 34 · cited 1×
“In endothelial progenitor cells, sem-aglutide inhibited lipopolysaccharide-induced macrophage expression of miR-155 in exosomes and improved cell viability and inflammatory status [17].”
BackgroundLambadiari, V., Pavlidis, G., Kousathana, F., Maratou, E., Georgiou, D., Andreadou, I., Kountouri, A., Varoudi, M., Balampanis, K., Parissis, J., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8070983 · Cited by 33 · cited 1×
“Several clinical studies which have investigated changes in vascular indices with GLP-1RAs have been published in recent years; however, data is still scarce [10-13].”
BackgroundSelf-citationBerndt, J., Ooi, S. L., & Pak, S. C. (2021) · Molecules · doi:10.3390/molecules26164822 · Cited by 33 · cited 1×
“In 5 of 7 clinical trials with cardiovascular outcome, statistically significant reductions in major cardiovascular adverse events (MACE) were re-ported, and these effects were independent of their glucose-lowering actions [6].”
BackgroundSuccurro, E., Marini, M. A., Fiorentino, T. V., Perticone, M., Sciacqua, A., Andreozzi, F., & Sesti, G. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110027 · Cited by 32 · cited 1×
“Current evidence shows that women with prediabetes and T2DM have higher risk for NAFLD than men [4].”
BackgroundEffects of semaglutide on vascular structure and proteomics in high-fat diet-induced obese mice
Yue, L., Chen, S., Ren, Q., Niu, S., Pan, X., Chen, X., Li, Z., & Chen, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.995007 · Cited by 32 · cited 1×
“An improvement in aortic injury was also detected in obese C57BL/6J mice, sema-glutide reduced PWV, and histology analysis showed decreased collagen levels and attenuated elastin damage [21].”
BackgroundGallego-Colón, E., Kłych‐Ratuszny, A., Kosowska, A., Garczorz, W., Aghdam, M. R. F., Woźniak, M., & Francuz, T. (2017) · Pharmacological Reports · doi:10.1016/j.pharep.2017.10.003 · Cited by 31 · cited 1×
“…reduced the intimal and medial area by ∼ 66% and ∼ 11%, respectively and reduced inflammatory markers [18], and this anti-inflammatory, antiproliferative effect on vascular remodeling has been observed with GLP-1RAs in previous in vitro studies with vascular smooth muscle cells [19, 20].”
BackgroundSavvidou, S., Karatzidou, K., Tsakiri, K., Gagalis, A., Hytiroglou, P., & Goulis, J. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.12.003 · Cited by 30 · cited 1×
“GLP-1RAs also restore serum levels of adiponectin [40], inhibit de novo lipogenesis and peroxisome proliferator-activated receptor gamma (PPAR-γ ) expression [41].”
BackgroundNavodnik, M. P., Janež, A., & Žuran, I. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071945 · Cited by 28 · cited 1×
“A direct comparison with our study can be made only with the work by Navodnik et al [22], who enrolled patients with type 1 diabetes mellitus and measured FMD and forearm blood flow as parameters of endothelial function, as well as PWV and peripheral resistance as parameters of arterial stiffness.”
ResultHarada, P. H. N., Benseñor, I. M., Drager, L. F., Goulart, A. C., Mill, J. G., & Lotufo, P. A. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.02.005 · Cited by 23
Jensen, D. M., Skovsted, G. F., Bonde, M. F. B., Bentzon, J. F., Rolin, B., Franck, G., Ougaard, M. K., Voetmann, L. M., Bachmann, J. C., Uryga, A., et al. (2022) · Atherosclerosis Plus · doi:10.1016/j.athplu.2022.05.004 · Cited by 20 · cited 1×
“…and blood flow perturbation, semaglutide reduced the intimal and medial area by ∼ 66% and ∼ 11%, respectively and reduced inflammatory markers [18], and this anti-inflammatory, antiproliferative effect on vascular remodeling has been observed with GLP-1RAs in previous in vitro studies with…”
BackgroundIncretin treatment and atherosclerotic plaque stability: Role of adiponectin/APPL1 signaling pathway
Barbieri, M., Marfella, R., Esposito, A., Rizzo, M. R., Angellotti, E., Mauro, C., Siniscalchi, M., Chirico, F., Caiazzo, P., Furbatto, F., et al. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.10.001 · Cited by 19 · cited 1×
“In addition, liraglutide reduced tumor necrosis factor alpha (TNF α )-induced nuclear factor kappa B activation in HUVECs, along with the expression of adhesion molecules, such as VCAM-1 and MCP-1 [29].”
BackgroundErrafii, K., Khalifa, O., Al-Akl, N. S., & Arredouani, A. (2022) · Biomedicines · doi:10.3390/biomedicines10051020 · Cited by 17 · cited 1×
“GLP-1RAs also restore serum levels of adiponectin [40], inhibit de novo lipogenesis and peroxisome proliferator-activated receptor gamma (PPAR-γ ) expression [41].”
BackgroundYu, X., Song, X., Tong, Y., Wu, L., & Song, Z. (2020) · Medicine · doi:10.1097/md.0000000000023360 · Cited by 12 · cited 1×
“In the study by Yu et al [45], it was found that significant fibrosis in NAFLD had an independent association with increased arterial stiffness after adjustment for cardiovascular risk factors, and the results in other studies were similar [46-48].”
Result
Cited by
Moiz, A., Filion, K. B., Tsoukas, M. A., Yu, O. H. Y., Peters, T. M., & Eisenberg, M. J. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103363 · Cited by 157
Michalopoulou, E., Thymis, J., Lampsas, S., Pavlidis, G., Katogiannis, K., Vlachomitros, D., Katsanaki, E., Kostelli, G., Pililis, S., Pliouta, L., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14020428 · Cited by 76
“In addition, another study shows that treatment with semaglutide resulted in a reduction in the Controlled Attenuation Parameter (CAP) score, E fibrosis score, NAFLD fibrosis score, and fibrosis-4 (FIB-4) score [117,118].”
Self-citationMechanism of Semaglutide in MASLD Treatment: Where Is the Master Key?
Ezhilarasan, D. (2025) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.17037 · Cited by 28
“Semaglutide treatment for 12 months reduced arterial stiffness, improved endothelial function, and decreased liver steatosis and fibrosis in T2DM patients with MASLD, indicating concurrent cardiovascular benefits [76].”
The multifaceted effects of semaglutide: exploring its broad therapeutic applications
Alkhatib, M., Almasri, N., Alshwayyat, S., Almahariq, H., Hammadeh, B. M., Taimeh, Z., Alkhatib, L., Alshwayat, A. R. I., Saadeh, N. A., & Al‐kurdi, M. A. (2025) · Future Science OA · doi:10.1080/20565623.2025.2483607 · Cited by 17
“An Rct involving 50 patients [51] indicated a significant improvement in liver fibrosis, whereas two other Rcts reported non-significant improvements compared with placebo [48].”
Bołdys, A., Bułdak, Ł., Nicze, M., & Okopień, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125883 · Cited by 9
“These outcomes are comparable to those reported for semaglutide in patients with NAFLD and type 2 diabetes mellitus, where CAP values decreased from 319 ± 37 to 283 ± 46 dB/m ( p 0.001) [21].”
Influential
Metadata
- Authors
- Korakas, E., Kountouri, A., Pavlidis, G., Oikonomou, E., Vrentzos, E., Michalopoulou, E., Tsigkou, V., Katogiannis, K., Pliouta, L., Balampanis, K., Pililis, S., Malandris, K., Tsapas, A., Siasos, G., Ikonomidis, I., & Lambadiari, V.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- Aristotle University of Thessaloniki (GR)
- Clinical Research and Evidence-Based Medicine Unit, Aristotle University of Thessaloniki , 54124 Thessaloniki , Greece
- Corresponding author
- Lambadiari, Vaia
- ORCID
- Korakas, Emmanouil
- Kountouri, Aikaterini
- Pavlidis, George
- Oikonomou, Evangelos
- Vrentzos, Emmanouil
- Michalopoulou, Eleni
- Tsigkou, Vasiliki
- Katogiannis, Konstantinos
- Pliouta, Loukia
- Balampanis, Konstantinos
- Pililis, Sotirios
- Malandris, Konstantinos
- Tsapas, Apostolos
- Siasos, Gerasimos
- Ikonomidis, Ignatios
- Lambadiari, Vaia
- Venue
- Journal of the Endocrine Society
- Publisher
- The Endocrine Society
- Published
- 2024-07-01
- Volume
- 8
- Issue
- 8
- Pages
- bvae122-bvae122
- ISSN
- 2472-1972 (ISSN-L)
- PMC
- PMC11228545
- OpenAlex
- W4400423778
- Cited by
- 18
- References
- 50
- Citations by year
- 2026: 8 · 2025: 9 · 2024: 1
- FWCI
- 5.93
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of the Endocrine Society (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- semaglutide, type 2 diabetes, non-alcoholic fatty liver disease, arterial stiffness, endothelial function, liver fibrosis, hepatic steatosis, pulse wave velocity, augmentation index, controlled attenuation parameter, DPP-4 inhibitors, cardiovascular risk
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.